COX Nicox SA

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

Press Release
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021
 



January 29, 2021 – release at 7:30 am CET

Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period of interest-only payments on the outstanding principal starting on February 1, 2021, and an extension of the overall period of the loan by 6 months to July 2024.  The new one-year interest-only period is expected to provide approximately €5.5 million of additional flexibility for investment in development activities in 2021.  The interest rate of the bonds remains unchanged as a result of this amendment.  Nicox has granted Kreos Capital 100,000 warrants for 100,000 Nicox shares, equivalent to approximately 0.27% of the present outstanding capital of the Company.



Michele Garufi, Chairman and Chief Executive Officer of Nicox, said: “Amending this bond financing agreement with Kreos Capital provides Nicox with greater financial flexibility for our exciting advanced development stage product candidates.  We are now recruiting in four late-stage clinical trials, one of which is conducted by our Chinese partner Ocumension.  These programs are expected to reach significant milestones in the next 12 to 18 months, including top-line clinical data on our two major assets, NCX 470 and NCX 4251.



As of February 1, 2021, the outstanding capital under the bond financing agreement with Kreos Capital signed in January 2019 shall be €16.1 million.  Under the amendment announced today, the repayment of the outstanding principal will restart on February 1, 2022, and will be completely repaid by July 2024.  Full details of the bond agreement can be found in the press releases of January 25, 2019 – and October 10, 2019 – .



Nicox also has €2 million of debt in the form of a credit agreement with Société Générale and LCL, guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic.



Warrant Terms



Kreos received 100,000 warrants, each giving a right to subscribe one share in Nicox at an exercise price of € 4.23 set in accordance with the 7th resolution of the Extraordinary Shareholder Meeting of June 30, 2020.  The warrants are exercisable immediately and over a 5-year period.  No specific restriction applies to the exercise of the warrants.  The shares obtained by exercise of the warrants will be ordinary shares of Nicox listed on Euronext Paris.



The exercise of the warrants would not materially dilute existing shareholders.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. 



Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.



For more information on Nicox, its products or pipeline, please visit: .
About Kreos Capital
Kreos Capital is the leading provider of growth-debt financing to high-growth companies in Europe and Israel with revenues up to €300 million.  Since 1998, as the pioneer growth debt provider across Europe and Israel, Kreos has completed 540 transactions and committed more than €2.3 billion in 15 different countries.  Kreos is dedicated to supporting management teams and their equity investors with flexible loan structures for all stages of a growth company’s development and to address the needs for growth capital, working capital, acquisition financings, lower mid-market buy-outs, roll-up strategies, banks re-financings, as well as pre- and post-IPO financings.  Kreos’ most recent fund, €700 million Kreos VI, was launched in January 2019.  The Kreos global team has extensive debt financing, management, and equity investing experience, covering the markets in Europe and Israel from its locations in London, Tel-Aviv, Berlin and Stockholm.
Analyst coverage
 



Bryan, Garnier & Co                  Victor Floc’h          Paris, France

Cantor Fitzgerald                      Louise Chen          New York, U.S.

Edison Investment Research   Pooya Hemami      London, UK

H.C. Wainwright & Co               Yi Chen                  New York, U.S.

Kepler Cheuvreux                      Damien Choplain  Paris, France
 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current.  Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox

Gavin Spencer

Executive Vice President, Chief Business Officer

& Head of Corporate Development 

T +33 (0)4 97 24 53 00

Investors & Media

United States & Europe

LifeSci Advisors, LLC

Mary-Ann Chang

T 3

Media

France

LifeSci Advisors, LLC

Sophie Baumont

M +33 (0)6 27 74 74 49

Forward-Looking Statements
The information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.



Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website () and (ii) as restated in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.
Nicox S.A.

Drakkar 2

Bât D, 2405 route des Dolines

CS 10313, Sophia Antipolis

06560 Valbonne, France

T +33 (0)4 97 24 53 00

F +33 (0)4 97 24 53 99

 

Attachment



EN
29/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclu...

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa wil...

 PRESS RELEASE

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 mi...

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Communiqué de presseNicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Un paiement initial de 7,5 millions d’euros, avec des paiements d’étapes de développement et de commercialisation pouvant atteindre un total de 191,5 millions...

 PRESS RELEASE

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clin...

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, its lead comp...

 PRESS RELEASE

Nicox annonce que le dernier patient a terminé l’essai clinique de Pha...

Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Communiqué de presseNicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470 Les premiers résultats sont attendus entre mi-août et mi-septembre 2025 L’autorisation de mise sur le marché (NDA) au Etats-Unis est prévu pour le premier semestre 2026 30 Juin 2025 – publication à 7H30 Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que le...

 PRESS RELEASE

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting ...

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company’s headquarters locate...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch